WAVEMAN · COMPANY

INVA · Innoviva, Inc.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

INVA

Name: Innoviva, Inc. (INVA) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Innoviva, Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001080014

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

182

13F, latest reported quarter

REVENUE GROWTH

+14.7%

XBRL, annual

NET MARGIN

65.9%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

182 funds added or opened last quarter

more than 84% of Pharma & Biotech

REVENUE

+14.7% year over year

more than 64% of Pharma & Biotech

MARGIN

65.9% net margin

more than 96% of Pharma & Biotech

BUYBACKS

$51.3M repurchased, FY to 2026-06-30

more than 58% of Pharma & Biotech

SHORT

9.5% of shares outstanding short · 11.5 days to cover · settled 2026-07-31

more than 74% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

182 funds added or opened positions in the latest 13F quarter, of 311 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +2.3%

+2.3%12M

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 182 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Innoviva, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

DENNER ALEXANDER J

—

SELL

2025-03-06

1,196,746.0

$21.0M

DENNER ALEXANDER J

—

SELL

2025-03-05

270,374.0

$4.8M

DENNER ALEXANDER J

—

SELL

2025-03-04

151,175.0

$2.7M

Zhen Marianne

Chief Accounting Officer

SELL

2023-11-15

5,589.0

$78.3K

Zhen Marianne

Chief Accounting Officer

SELL

2023-11-15

5,405.0

$75.5K

21 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 16 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

11,555,209.0 sh

$262.4M

DIMENSIONAL FUND ADVISORS LP

4,494,053.0 sh

$102.1M

VANGUARD PORTFOLIO MANAGEMENT LLC

4,220,273.0 sh

$95.8M

RENAISSANCE TECHNOLOGIES LLC

4,036,532.0 sh

$91.7M

STATE STREET CORP

3,268,004.0 sh

$74.2M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Invesco Pharmaceuticals ETF

$9.6M POSITION · AS OF 2026-04-30

2.9%

RIVER OAK DISCOVERY FUND

$409.0K POSITION · AS OF 2026-04-30

2.7%

WPG Partners Select Small Cap Value Fund

$5.5M POSITION · AS OF 2026-02-28

2.6%

ETC 6 Meridian Small Cap Equity ETF

$2.9M POSITION · AS OF 2026-02-28

2.3%

State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF

$6.1M POSITION · AS OF 2026-03-31

2.0%

PROFUND VP PHARMACEUTICALS

$194.6K POSITION · AS OF 2026-03-31

1.9%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$411.3M	$358.7M	$310.5M	$331.3M
GROSS PROFIT	$307.7M	$296.2M	$246.0M	—
OPERATING INCOME	$163.7M	$166.9M	$113.9M	—
NET INCOME	$271.2M	$23.4M	$179.7M	$220.3M
EPS (DILUTED)	3.30	0.36	2.20	2.37
OPERATING CASH FLOW	$196.9M	$188.7M	$141.1M	$201.7M
CASH	$550.9M	$305.0M	$193.5M	$291.0M
LONG-TERM DEBT	$257.7M	$256.3M	$446.2M	$444.2M
BUYBACKS	$4.5M	$14.8M	$75.7M	$8.5M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE